// App-Quantinova.ai

BSH19‐PO‐092 : Nivolumab, Brentuximab Vedotin, and Bendamustine as Response‐Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard‐Risk Cohort of the Phase 2 Checkmate 744 Study

Researchers

Presenter

  • P. Harker-Murray

Principal Investigators

  • T. Leblanc

  • M. Mascarin

  • C. Mauz-Krholz

  • G. Michel

  • S. Cooper

  • A. Beishuizen

  • K. Leger

  • A. Garaventa

  • S. Buffardi

  • L. Brugieres

  • K. Kelly

  • P. Cole

  • R. Drachtman

  • F. Galderisi

  • M. Sacchi

  • S. Francis

  • S. Daw

Medical Centers

  • Medical College of Wisconsin, Milwaukee, Wisconsin , United States

  • Hopital Robert Debre, AP-HP, Paris, France

  • Centro di Riferimento Oncologico-IRCCS, Aviano, Italy

  • University Hospital Justus Liebig University, Giessen and Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle, Germany

  • Hospital de la Timone, Marseille, France

  • Johns Hopkins, Baltimore, United States

  • Princess Maxima Center for Pediatric Oncology, Netherlands

  • Seattle Childrens Hospital, Seattle, Washington, United States

  • IRCCS Istituto Giannina Gaslini, Genoa

  • Santobono ‐ Pausilipon Hospital, Napoli, Italy

  • Institut Gustave-Roussy, Villejuif, France

  • Roswell Park Cancer Institute, Buffalo, NY

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Seattle Genetics, Bothell, WA

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Kings College London, London, United Kingdom

Locations

  • United States

  • France

  • Italy

  • Germany

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Anaphylaxis

  • Neutropenia

  • Lymphomas

Biomarkers

  • Hematocrit

Drug/Treatment

  • Adcetris

  • Bendamustine

  • Nivolumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02927769

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved